NWMP
PTGX icon

Noble Wealth Management PBC’s Protagonist Therapeutics PTGX Stock Holding History

Noble Wealth Management PBC’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.13K Hold
8
– – ﹤0.01% 659
2026
Q2 		$981 Buy
+8
New +$836 ﹤0.01% 709

Other funds holding PTGX

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Noble Wealth Management PBC's PTGX Position: Q3 2026 in Review

Noble Wealth Management PBC held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 8 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #659.

Noble Wealth Management PBC first reported a position in PTGX in Q2 2026 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Noble Wealth Management PBC held 8 shares of Protagonist Therapeutics worth $1.13K as of Q3 2026.
  • Noble Wealth Management PBC left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Noble Wealth Management PBC's portfolio in Q3 2026, its #659 holding.
  • Noble Wealth Management PBC first reported a position in Protagonist Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Noble Wealth Management PBC's 13F filing for Q3 2026, filed 1 Oct 2026.